Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01429519
Other study ID # RGN-WH-001
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date December 2011
Est. completion date December 2012

Study information

Verified date August 2018
Source Regenera Pharma Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objectives are to evaluate safety and efficacy of topical administration of RPh201 oil solution (botanical extract) for treatment of patients with hard to heal chronic ulcerated wounds.


Description:

The study objectives are to evaluate safety and efficacy, of topical administration of RPh201 for treatment of patients with hard to heal wounds.

This is to include:

- Safety evaluation of RPh201 (botanical extract) formulated as an oil solution administered topically three times per week during an overall treatment period of up to 4 weeks in patients with hard to heal wounds.

- Efficacy assessment of wound improvement following the use of RPh201 oil solution (botanical extract) administered topically three times per week during an overall treatment period of up to 4 weeks and at the follow-up visit at 3 months after end of treatment in patients with hard to heal wounds


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Participants, either men or women are = 18 years of age.

2. Patients must have at least one hard to heal wound of different etiologies (venous insufficiency, lymphatic insufficiency, neuropathic wounds or diabetic ulcers, post- operative and post-traumatic chronic wounds) located on the leg shin or foot.

3. The wound is refractive to healing at least 4 weeks prior to treatment, although treated by routine practice.

4. Wound area size is in the range of: 3 - 36 square centimeters.

5. Patients defined as grade C or above on the granulometer scale (see section 6.5.1).

6. Participants understand the nature of the procedure and provide written informed consent prior to any study procedure.

7. Women of child bearing potential must use adequate birth-control precautions.

Exclusion Criteria:

1. Clinically significant arterial vascular disease with ABI index <0.45 if the peripheral pulse is not palpable, or flatted PVR in case of non palpable arteries.

2. Clinical evidence for presence of infection in the soft tissue, joint and/or bone (osteomyelitis).

3. Wound has Non-viable tissue which covers more than 50% of the wound area.

4. Patients with skin disorders unrelated to the ulcer that are presented adjacent to the wound.

5. The wound penetrates into deep organs and involves bone, tendon or joint

6. Wound with sinus tracts

7. Patients are receiving, or have received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.

8. Treatment with a dressing containing growth factors or other biological dressings within 15 days, prior to the screening visit.

9. Patients that have a history of alcohol or drug abuse within the last two years.

10. Female patients who are pregnant or nursing, or of childbearing potential and are not using adequate contraception.

11. Participation in another clinical trial within 30 days prior to the Screening Visit or during this study.

12. Clinically significant and/or uncontrolled condition or other significant medical disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RPh201, botanical drug product
topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day

Locations

Country Name City State
Israel High Risk Foot Clinic - Maccabi Health Services Tel-Aviv

Sponsors (2)

Lead Sponsor Collaborator
Regenera Pharma Ltd TransCom Global Ltd. (CRO)

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the safety use of RPh201 administered topically three times a week during an overall treatment period of up to 4 weeks, with 52 days follow-up Safety evaluation - To demonstrate safety using the RPh201 oil solution in terms of skin irritation score to be less than 2 for erythema /edema individual subject's results or less then 1.9 for Primary Irritation Index (PII) category (see section 6.5.2 and APPENDIX 2) .
Safety evaluation - To demonstrate safety of using RPh201 oil solution in terms of type and severity of adverse events.
90 days
Secondary To obtain preliminary data on the efficacy of RPh201 on improving wound status in patients with hard to heal chronic ulcerated wounds Evaluation of the correlation between the treatment period and changes in wound area size.
Assessment of wound closure state in terms of % Non-viable area, % granulation tissue appearance,
Assessment of wound closure state in terms of time to wound closure.
Assessment of pain based on a pain analog scale of 1-10.
90 days
See also
  Status Clinical Trial Phase
Completed NCT05076578 - A Prospective Clinical Study Evaluating the Harvesting of Micografts N/A
Recruiting NCT04887688 - Exciflex for Chronic Wound Therapy N/A
Terminated NCT03738579 - Evaluating Wound Healing With Next Science Gel & Wash. N/A
Enrolling by invitation NCT06444035 - Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome N/A
Completed NCT02417805 - Cutaneous Microcirculation After Remote Ischemic Preconditioning N/A
Completed NCT02417779 - Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy N/A
Completed NCT02417818 - Cutaneous Microcirculation After Plasma Therapy N/A
Completed NCT03662997 - Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds N/A
Not yet recruiting NCT04132635 - A Trial to Evaluate the Combination Efficacy of Artificial Dermis and Growth Factor in Chronic Wounds Ulcer N/A
Withdrawn NCT01646502 - Treatment of Chronic Wound Biofilms N/A
Recruiting NCT05342740 - Study of Biomarkers in Diabetic Chronic Wounds
Suspended NCT02577120 - Wound Healing Endpoint and Recurrence Phase 4
Recruiting NCT06185465 - Effectiveness and Safety of Using Prontosan to Treat Bacterial Biofilm N/A
Completed NCT04514783 - Healthy Tissue Preservation During Wound Debridement by Using Debritom+ Micro Water Jet Technology N/A
Not yet recruiting NCT05974228 - Bioglass Wound Dressing in Treatment of Chronic Wound in Different Stageļ¼ša Randomized Controlled Trial N/A
Recruiting NCT05414916 - Pain Relief Strategies for Dressing Change in Chronic Wounds
Recruiting NCT04019639 - Efficacy of Paste Type Acellular Dermal Matrix(CG Paste) in Chronic Wound Healing N/A
Completed NCT05810649 - Local Injection for the Treatment of Chronic Wounds and Pain Caused by Chronic Wounds N/A